biotech / news / / Scientific American
A weekly injection of 12 milligrams (0.19 grain) of retatrutide for 80 weeks helped people lose almost 30 percent of their body weight.
Retatrutide helped participants lose almost 30 percent of body weight over 80 weeks in a phase 3 trial.
KEY POINTS
- Retatrutide targets three receptors—GLP-1, glucagon, and GIP—unlike current drugs targeting one or two.
- At the highest dose tested, participants lost 28.3 percent of their body weight on average.
- About one-third of participants experienced nausea or diarrhea, while up to a quarter experienced vomiting.
COMPANIES
Summarized by Newsio from Scientific American. How we summarize →